Pharmaceutical Technology

JUNE 15, 2023

Eloxx has revealed its lead candidate ELX-02 improved predicted forced expiratory volume (ppFEV1) in patients with Class 1 cystic fibrosis (CF) in a new analysis of a Phase II trial that missed its efficacy endpoints. The regimen in the trial was a one-week monotherapy period (1.5

Trials 246

Trials Genetics Protein Marketing 246

Fierce Pharma

JULY 27, 2023

Astellas signed another protein degrader deal, this time with PeptiDream. Astellas signed another protein degrader deal. Takeda's enzyme replacement therapy flunked a mid-stage trial in a rare neurological disorder. Daiichi Sankyo's FLT3 inhibitor overcame FDA rejection to win an approval. Plus more.

Protein 93

Protein Trials 93

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 52

Trials Clinical Trials Clinical Trials Protein 52

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 These results came from data from Novavax’s Phase III UK trial where B.1.117

Protein 97

Protein Vaccination Vaccine Trials 97

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. The post Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2 appeared first on.

Protein 122

Protein Immune Response Vaccination Vaccine 122

Bio Pharma Dive

MAY 19, 2023

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 290

RNA Medicine Clinical Trials Clinical Trials 290

Bio Pharma Dive

MARCH 30, 2021

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.

Life Science 303

Life Science Drugs Trials Protein 303

pharmaphorum

MARCH 19, 2021

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with protein misfolding. . The post Protein misfolding specialist Gain nets $40m from IPO appeared first on. and valuing the company at around $130 million.

Protein 103

Protein Gene Editing Drugs Clinical Trials 103

Bio Pharma Dive

SEPTEMBER 9, 2021

The French drugmaker bought Principia Biopharma last year for two therapies that block a protein called BTK. The second targets a much bigger disorder, multiple sclerosis.

Protein 294

Protein Trials Drugs 294

Pharmaceutical Technology

MAY 4, 2023

ARTHEx Biotech will use the funds to advance an antimiR oligonucleotide, ATX-01, to a Phase I/IIa clinical trial in the second half of 2023. It has a dual mechanism of action that targets toxic dystrophia myotonica protein kinase and MBNL protein.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Protein 130

Drug Discovery World

FEBRUARY 27, 2024

Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. The post First PROTAC degrader for neurodegenerative disease enters trials appeared first on Drug Discovery World (DDW).

Trials 52

Trials Protein Clinical Trials Clinical Trials 52

Drug Discovery World

DECEMBER 19, 2023

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). The post World’s first engineered B cell therapy enters human trials appeared first on Drug Discovery World (DDW).

Engineer 113

Engineer Trials Genetic Disease Gene Therapy 113

Pharmaceutical Technology

JUNE 20, 2023

Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein. The vaccine is based on recombinant protein vaccine technology and is suitable for storage between 2°C and 8°C.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

XTalks

JULY 19, 2022

The two-dose protein-based, adjuvanted vaccine has been authorized for use in adults 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. In a press release outlining the authorization, the FDA noted that the clinical trial for Novavax’s vaccine was conducted before the appearance of the omicron and delta variants.

Vaccination 94

Vaccination Vaccine Protein Clinical Trials 94

Roots Analysis

MARCH 2, 2022

Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Pipeline Overview of Oral Peptide and Protein-based Therapeutics. Oral Protein / Peptide-based Drugs. Oral Protein / Peptide-based Drugs.

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

Fierce Pharma

APRIL 29, 2024

After spearheading the new HER2-low category in breast cancer treatment, Enhertu has shown it could be useful against tumors with even lower expression of the HER2 protein. . | AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself.

Protein 98

Protein Trials 98

BioTech 365

JULY 6, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Lilly invests in MiNA to fund trials of protein-upregulating RNA.Lilly invests in MiNA to fund trials of protein-upregulating RNA ntaylor Tue, 07/06/2021 – 07:58 from FierceBiotech: Biotech … Continue reading → (..)

RNA 40

RNA Protein Trials Research 40

Bio Pharma Dive

MARCH 30, 2022

A drug regimen including Roche's top prospect tiragolumab didn't outperform standard treatment in its first large trial, a setback for therapies aimed at a protein called TIGIT.

Protein 288

Protein Trials Drugs 288

Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response 75

Immune Response Protein Clinical Trials Clinical Trials 75

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 29, 2024

The mutation is in the gene for a protein called programmed death-ligand 1 (PD-L1), and a […] A unique genetic mutation in two siblings – that has never been seen in anyone else – has been discovered by UK researchers at the University of Exeter, pointing the way towards new treatment options for type 1 diabetes.

Gene 183

Gene Genetics Protein Research 183

BioTech 365

MAY 28, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: HCW files for $50M IPO to trial fusion protein in solid tumors.HCW files for $50M IPO to trial fusion protein in solid tumors ntaylor Fri, 05/28/2021 – … Continue reading →

Protein 40

Protein Trials Research 40

Drug Discovery World

FEBRUARY 28, 2024

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. Each of the three vaccines in Tri-Ad5 targets different proteins associated with precancer and cancer cells.

Vaccination 52

Vaccination Vaccine Trials Protein 52

Bio Pharma Dive

JUNE 5, 2023

Results from a “basket” trial of the antibody-drug conjugate show it shrank tumors across a half dozen cancers, suggesting a broader role to targeting the protein HER2.

Drugs 180

Drugs Protein Antibody Trials 180

Drug Discovery World

AUGUST 23, 2022

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . The disease is caused by anomalous repeating mutations in the huntingtin gene leading to abnormal protein aggregates in nerve cells.

Gene Therapy 98

Gene Therapy Gene Trials Clinical Trials 98

BioTech 365

AUGUST 5, 2021

Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine First Phase II subjects dosed with AKS-452, COVID-19 … Continue reading →

Clinical Trials 52

Clinical Trials Clinical Trials Protein Vaccination 52

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 It is self-assembled into stable trimeric protein particles with the addition of squalene-based oil-in-water emulsion adjuvant following purification and mixing.

Vaccination 269

Vaccination Vaccine HR Protein 269

pharmaphorum

FEBRUARY 10, 2022

The 3rd Protein Degradation and Targeting Undruggables Summit is North America’s only in-person, industry-led conference covering clinical progress and commercial scale development of first-in-class degrader technology platforms. The post The Protein Degradation & Targeting Undruggables Congress appeared first on.

Protein 52

Protein Development Drugs Clinical Trials 52

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 11, 2024

Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.

Vaccination 173

Vaccination Vaccine Bacteria Protein 173

Scienmag

FEBRUARY 23, 2021

(February 23, 2021) – The Gates Biomanufacturing Facility (GBF) has completed the manufacturing and release of a protein-based biologic under Good Manufacturing Practice for Phase 1 Investigational Drugs for first-in-human clinical trials.

Protein 57

Protein Manufacturing Clinical Trials Clinical Trials 57

BioTech 365

JUNE 23, 2021

Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer … Continue reading →

Clinical Trials 52

Clinical Trials Clinical Trials Protein Trials 52

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 5, 2024

The first twin study of its kind suggests that taking daily protein and prebiotic supplements can improve scores on memory tests in people over the age of 60. What’s good for your aging gut may also be good for your aging brain. The findings are food for thought, especially as the same visual memory and […]

Protein 197

Protein Clinical Trials Clinical Trials Clinical Research 197

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. These trials comprised the Phase III VAT08 Stage 2 trial analysing initial efficacy and two other immunogenicity trials.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Bio Pharma Dive

MARCH 22, 2023

Though the drug, called tofersen, missed the main goal of a key clinical trial, it showed an effect on a protein tied to ALS. Experts see that as a good sign, but some worry Biogen has not yet gathered enough supportive evidence.

Drugs 174

Drugs Clinical Trials Clinical Trials Protein 174

XTalks

FEBRUARY 19, 2024

The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine. The comparison is particularly important as gB/MF59 demonstrated promise in Phase II clinical trials but did not advance to Phase III.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Drug Discovery World

NOVEMBER 8, 2023

Deepika Khedekar , Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Tapping into the capabilities of AI One reason AI may accelerate clinical trials is its ability to rapidly process and analyse vast amounts of data.

Clinical Trials 72

Clinical Trials Clinical Trials Trials Drugs 72

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 2, 2024

Alzheimer’s disease is commonly associated with clumps and tangles of proteins building up in brain cells. Yet for more than a century, accumulations of a completely different material have also been linked with the neurodegenerative condition.

Protein 161

Protein Medicine Research Clinical Trials 161